Windber Research Institute chooses Teradata storage technology

TriMed Staff | | Health Imaging | Practice Management
Biomedical research facility Windber Research Institute (WRI) has tapped Teradata to create a central data warehouse for the storage of molecular and clinical information, which will be used to help find the cause of breast and other forms of cancer.

 WRI is assembling data from several sources, including GenBank (DNA sequences for further analysis), PubMed (scientific literature), SWISS-PROT (protein information for further analysis), and DIP (protein-protein interactions), which are then linked to WRI's own molecular (DNA, RNA, protein) and clinical data.

 WRI said it chose the division of NCR Corp., because it can integrate data from multiple sources simultaneously. Teradata technology will enable Windber to store, retrieve, analyze and manage the massive amount of data generated at the DNA, RNA and protein levels by using large-scale biology technologies.

TriMed Staff

Related Content

Newly launched report feature provides patients with a visual aid to their imaging
Center for Devices and Radiological Health hit with federal job cuts
Overview of the regulatory landscape of AI in radiology
Concerns about private equity's growing influence in radiology
'Ad hoc' shifts and radiology 'maestros': How one department addressed its workflow hiccups
Not all lead glasses are created equal

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.